PostYou are now at: Home » Products » Chemicals » Chemical Reagent »

Ulipristal acetate CAS 126784-99-4 (jerryzhang001@chembj.com)

Click image to view original image
Brand: NJBN STEROID
型号: 126784-99-4
Price: 2.00USD/g
Min.Order: 10 g
Supply
Delivery: Shipment within 3 days since the date of payment
Address: China
Valid until: 2024-11-30
Updated on: 2016-11-16 13:21
Hits: 688962
Enquiry
Company Detail
 
 
Details

Ulipristal acetate  CAS 126784-99-4  

Ulipristal acetate

Synonym: EllaOne, Ulipristal ace
CAS: 126784-99-4
M.F.: C28H35NO3
M.W.: 433.5824
Appearance: White crystalline powder
Usage: contraceptive medicine anabolic powder
Storage: Kept Ulipristal acetate in a cool, dry and ventilated place
We guarantee good quality products. 100% refunded if parcel is not delivered or poor quality.

 Description

Ulipristal acetate (trade name EllaOne in the European unio, Ella in the U.S. for contraception, and Esmya for uterine fibroid) is a selective progesterone receptor modulator (SPRM).

Medical Uses

Emergency contraception:

For emergency contraception a 30 mg tablet is used within 120 hours (5 days) after an unprotected intercourse or contraceptive failure. It has been shown to prevent about 62–85% of expected pregnancies, and prevents more pregnancies than emergency contraception with levonorgestrel. Ulipristal acetate is available by prescription for emergency contraception in over 50 countries, with access through pharmacists without a prescription being tested in the United Kingdom. From July 2016 available without prescription in Israel.

Treatment of uterine fibroids

Ulipristal acetate is used for pre-operative treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age in a daily dose of a 5 mg tablet.

Treatment of uterine fibroids with ulipristal acetate for 13 weeks effectively controlled excessive bleeding due to uterine fibroids and reduced the size of the fibroids.

Two intermittent 3-months treatment courses of ulipristal acetate 10 mg resulted in amenorrhea at the end of the first treatment course in 79.5%, at the end of the second course in 88.5% of subjects. Mean myoma volume reduction observed during the first treatment course (−41.9%) was maintained during the second one (−43.7%). After two to four 3-months courses of treatment, UPA-treated fibroids shown about -70% in volume reduction. This phenomenon was temptatively explained by the combination of multifactorial events involving control of proliferation of the tumor cells, induction of apoptosis and remodeling of the extracellular matrix.

Total: 0 [Show All]  Related Reviews
 
More »Our Others Products

[ ProductsSearch ]  [ Add To Favourite ]  [ Tell Friends ]  [ Print Content ]  [ Violation Report ]  [ Close Window ]